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Abstract
Background: Catheter-related bloodstream infection (CRBSI) is one of the most frequent complications in patients
with cancer who have central venous catheters (CVCs) implanted and is associated with substantial morbidity and
mortality. Taurolidine is a non-antibiotic agent with broad-spectrum antimicrobial activity, which has been used as a
lock solution to prevent CRBSI in some settings. However, little is known about its usefulness in high-risk adult
neutropenic patients with cancer. This prospective randomised clinical trial aims to test the hypothesis that
taurolidine-citrate lock solution is more effective than placebo for preventing catheter infection in neutropenic
haematological patients.
Methods: This study is a prospective, multicentre, randomised, double-blinded, parallel, superiority,
placebo-controlled trial. Patients with haematological cancer who are expected to develop prolonged neutropenia
(> 7 days) and who have a non-tunnelled CVC implanted will be randomised to receive prophylactic
taurolidine-citrate-heparin solution using a lock technique (study group) or heparin alone (placebo group). The primary
endpoint will be bacterial colonisation of the CVC hubs. The secondary endpoints will be the incidence of CRBSI, CVC
removal, adverse events, and 30-day case-fatality rate.
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Discussion: The lock technique is a preventive strategy that inhibits bacterial colonisation in the catheter hubs, which
is the initial step of endoluminal catheter colonisation and the development of infection. Taurolidine is a nontoxic
agent that does not develop antibiotic resistance because it acts as an antiseptic rather than an antibiotic. Taurolidine
has shown controversial results in the few trials conducted in cancer patients. These studies have important limitations
due to the lack of data on adult and/or high-risk neutropenic patients, the type of catheters studied (tunnelled or
ports), and the lack of information regarding the intervention (e.g. dwelling of the solution, time, and periodicity of the
lock technique). If our hypothesis is proven, the study could provide important solid evidence on the potential
usefulness of this preventive procedure in a population at high risk of CRBSI, in whom this complication may
significantly impair patient outcome.
Trial registration: ISRCTN, ISRCTN47102251. Registered on 9 September 2015.
Keywords: Catheter-related bloodstream infection, Central venous catheter infection, Antibiotic lock technique,
Lock solution, Taurolidine-citrate, Haematological patients, Neutropenia
Background
Catheter-related bloodstream infection (CRBSI) is one of
the most frequent complications associated with the
long-term use of catheters. Patients with cancer usually
have central venous catheters (CVC) implanted for an
indefinite period for the administration of chemotherapy
and other products and medications and are at increased
risk of presenting with this complication, especially
during the neutropenic phase. CRBSI in patients with
cancer is associated with substantial morbidity and mor-
tality, with excess costs and prolonged length of hospital
stay [1–3]. Importantly, CRBSI can delay the administra-
tion of chemotherapy, which may negatively influence
patient outcomes [4].
Gram-positive organisms, mainly coagulase-negative
staphylococci (CNS) and Staphylococcus aureus, are the
leading cause of CRBSI in patients with cancer [1]. How-
ever, an increasing number of episodes of CRBSI due to
Gram-negative bacilli and fungi have been recently
documented in some institutions [5–7]. In addition, an
alarming emergence of antimicrobial resistance is being
observed among Gram-negative bacteria infecting high-
risk patients with malignancies [8, 9]. This is of special
concern due to the associated increased mortality of
bloodstream infections (BSI) due to resistant organisms
in neutropenic cancer patients [10–12].
The most frequent mechanism of infection with long-
term, non-tunnelled CVC use is catheter hub con-
tamination during catheter manipulation by health
personnel, leading to endoluminal colonisation and in-
fection [13, 14]. Bacterial colonisation of catheter lumens
leads to the development of a microbial consortium as-
sociated with the catheter surface and embedded in an
extracellular matrix, named biofilm, which hinders anti-
biotic penetration and bacterial eradication [15]. Cath-
eter removal and treatment with systemic antibiotics is
the ‘gold standard’ approach for CRBSI [14, 15]. How-
ever, in neutropenic cancer patients, the removal of their
‘highly needed’ catheter is not always feasible, even when
the diagnosis of catheter infection is established [16].
Therefore, prevention of CRBSI in these high-risk pa-
tients is crucial.
The use of lock therapy with different solutions as a
method of preventing luminal catheter colonisation is an
effective strategy in reducing CRBSI [17]. Lock therapy
involves instillation of a solution into the catheter lumen
for a variable period of time, depending on the solution
at hand [18]. Moreover, the use of lock therapy decreases
the incidence of CRBIS in some studies involving pa-
tients with cancer [19]. However, significant differences
in the definitions of CRBSI exist in the studies per-
formed, as well as in the type of catheters, the solutions
used, and the dwelling times. Additionally, almost all
studies have been performed in paediatric populations,
and the number of high-risk neutropenic patients in-
cluded in the studies is very small. In fact, national
guidelines do not currently support the prophylactic use
of lock therapy in patients with cancer, while waiting for
higher-quality scientific evidence.
Vancomycin, ethanol, and taurolidine have been the
most frequently studied lock solutions in patients with
cancer, with very variable results, according to the sig-
nificant aforementioned differences in the methodology
of the studies and the population involved [20–29]. Of
note, there is great concern regarding the use of
vancomycin as a lock solution, since there is a risk of de-
veloping antibiotic resistance. Furthermore, the adverse
events observed with the use of ethanol discourage its
use as a lock solution. Taurolidine is a non-toxic sub-
stance derived from the amino acid taurine, which has
anti-adherent, immunomodulatory, antithrombotic, and
antitumour properties [30]. Although it is not an
antibiotic, it has a wide array of antimicrobial activity
against a broad spectrum of microorganisms, including
Gram-positive bacteria, Gram-negative bacteria, and
fungi. Taurolidine-citrate was found to be effective in
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two [28, 29] of the three studies involving paediatric pa-
tients with cancer, reducing CRBSI rates compared with
heparin solutions, but it did not offer any benefit when
used in the single adult study performed in patients with
non-haematological cancer who had totally implantable
venous access ports implanted [31]. The scarce and
heterogeneous data obtained from these studies do not
draw any solid conclusion. Moreover, almost all reported
studies involved paediatric patients, and the devices
studied in all of these trials were tunnelled catheters
or ports.
This prospective, multicentre, randomised, double-
blinded, placebo-controlled trial aims to test the hypoth-
esis that lock solution with taurolidine-citrate-heparin
is more effective than placebo for preventing CVC
catheter infection in high-risk neutropenic haemato-
logical patients.
Objectives of the study
This study aims to determine whether taurolidine-
citrate-heparin lock solution is more effective than
heparin alone for the prevention of CVC infection in
neutropenic haematological patients.
Primary endpoint
Bacterial colonisation of the CVC hubs.
Secondary endpoints
Incidence of CRBSI, CVC removal, adverse reactions,
and 30-day case-fatality rate.
Methods
Study design
This study is a prospective, multicentre, randomised,
double-blinded, parallel, superiority, placebo-controlled
trial (1:1). Patients will be randomised after completion
of chemotherapy. Patients who were expected to de-
velop prolonged (> 7 days) neutropenia will be rando-
mised to receive a prophylactic solution of taurolidine-
citrate-heparin using the lock technique (study group)
or a solution with heparin alone using the same
technique (placebo group). The study will be conducted
in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
recommendations [32], Additional file 1.
Study population
This study includes adult patients with haematological
malignancies admitted to the haematology wards who
are receiving chemotherapy, who are expected to de-
velop prolonged neutropenia (> 7 days), and who have a
non-tunnelled CVC implanted.
Setting
The study will be conducted in Institut Català d’Oncologia
L’Hospitalet (ICO Hospitalet), a 100-bed capacity hospital
for adult patients, a referral cancer centre for a population
of one million people. University Hospital of Bellvitge
(HUB), an 800-bed-capacity tertiary hospital for adult pa-
tients. Both hospitals are located in the same health com-
plex and are part of the Institute of Biomedical Research
of Bellvitge (IDIBELL). Hospital Universitario Virgen del
Rocío (HUVR) is a 1700-bed capacity hospital that caters
to half a million inhabitants in the province of Seville.
Selection of cases and recruitment
Patients admitted in the haematology wards of the two
participating centres receiving myeloablative chemother-
apy and who are expected to develop prolonged neutro-
penia (> 7 days) will be followed up daily by the
attending physicians and by a research nurse specifically
commissioned to carry out this study. Screening swabs
from the catheter hubs and the catheter insertion site
will be collected previous to randomisation by the usual
nursing personnel; then, the catheter samples will be
sent to the microbiology laboratory in order to identify
patients with positive cultures (exclusion criteria). Pa-
tients with negative screening cultures will be followed
up daily by the research nurse in charge and/or the in-
vestigators of the study, to assess whether they meet all
the inclusion criteria and none of the exclusion criteria.
A blood test will be performed every 2–3 days according
to the protocols of each centre to document the devel-
opment of neutropenia. Patients with neutropenia who
met the inclusion criteria will be asked to sign the in-
formed consent. The research nurse in charge and/or
the investigators of the study will explain the study to
the potential participants and ask them to sign the in-
formed consent.
Inclusion criteria
1. Patients aged 18 years or older who are admitted to
the hospital because of leukaemia, lymphoma
or to undergo haematopoietic stem-cell
transplantation (HSCT)
2. Carriers of multiple-lumen, non-tunnelled
CVCs, including peripherally inserted central
catheters (PICCs)
3. Patients who are expected to develop neutropenia
(< 500 neutrophils/μL) lasting more than 7 days
A patient could be included twice if two independent
periods of neutropenia occur with at least 1 month
interval between them. This interval will be calculated
from the final visit (30 days from the end of the
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intervention) to the new inclusion. In this cases, patients
will be randomised again.
Exclusion criteria
1. Patients with a (non-flexible) semi-rigid or
tunnelled CVC or totally implantable venous
access ports
2. Patients who have been found to have a positive
culture of the hubs or the insertion site of the
CVC based on the results of the baseline
screening cultures
3. Patients in whom the CVC is indispensable for
the use of continuous infusion medication
4. Patients receiving systemic antibiotic treatment ≥ 48 h
prior to study entry
5. Patients with an active infection
Randomisation
In this randomised, double-blinded study, neither the
patient nor any of the health staff will know which prod-
uct is assigned to each patient.
A unique list of coded numbers containing the rando-
mised solutions will be generated in the Clinical Re-
search Unit. The randomisation will be performed in
each block and stratified. The stratum will contain three
groups: patients with leukaemia, patients undergoing an
autologous transplantation, and patients undergoing an
allogeneic transplantation. The random number gener-
ator of SAS version 9.2 will generate the three lists.
Once generated, the list will be kept in the pharmacy
file, in the pharmacy department of ICO Hospitalet with
restricted access to the blinded personnel involved in
the trial. When a patient from any of the two participat-
ing centres meets the inclusion criteria and signs the in-
formed consent, an email with the recruitment sheet of
the patient will be sent to the pharmacy department of
ICO Hospitalet, where the randomisation will take place,
by the investigator from the pharmacy department in
charge of the study. The assignment will be made
sequentially, and each patient will be assigned a random-
isation number.
The taurolidine-citrate-heparin and the heparin-
placebo solutions will be prepared in each pharmacy de-
partment, and they will be dispensed in 2.5-mL syringes
identified with the name of the drug, defined as heparin/
taurolidine-citrate, to maintain the blinding. Citrate is an
anticoagulant substance without antimicrobial activity,
which accompanies taurolidine as an antiaggregant
agent. Both lock solutions are colourless and odourless,
which makes further masking unnecessary. The blind
will be open before the statistical analysis, but only when
the trial has concluded and the definitive data will be
registered in the database. Only in cases with suspected
serious adverse events will the blinding be open.
Intervention
Once the randomisation has been performed, a syringe
containing 2.5 mL of the assigned lock solution (taurolidine
2%-citrate 4%-heparin 500 UI/mL, or heparin 1% alone at a
dose of 1000 UI/mL) will be injected, by usual haematol-
ogy ward nurses, through each catheter lumen three times
a week, approximately every 48-72 h. The solution will be
allowed to dwell for approximately 2 h. In all cases, the
solution will be aspirated with a syringe and discarded.
Before the lock technique, cultures of the hubs and the
CVC insertion site will be taken in order to assess the
bacterial colonisation of these sites. The research nurse in
charge of the study will supervise all the proceedings
related with the intervention. Also, the nurse in charge
will periodically provide a report to the principal investiga-
tor of the study, informing whether the interventions have
been performed properly.
Catheter management
Multilumen, non-tunnelled CVCs will be inserted into the
vein by a specifically trained staff, under the standard pre-
cautions. At the time of the catheter placement, the inser-
tion site will be disinfected with 2% chlorhexidine in an
alcohol base and then covered with a transparent dressing,
except in patients with allergy to this type of dressing, in
whom sterile gauze will be used. Also, when there is any
sign of inflammation at the insertion site, the dressing will
be replaced by a chlorhexidine-impregnated dressing. The
care of the CVCs will include the replacement of the
dressings every 6–10 days, or before if necessary. Before
any manipulation, the catheter hubs will be disinfected
using an external clean with 70° alcohol. If the catheter is
sealed, the hubs will be disinfected every 6–10 days. If any
of the catheters lumens become sluggish or occluded,
flushing with urokinase will be performed. Any change of
these procedures will be recorded in the database. The
manipulations of the CVCs will be carried out under max-
imum barrier measures.
Follow-up criteria and participant timeline
Patients will continue to receive intervention until one
of following events occurs:
1. Positivity of any of the cultures taken from the
CVC hubs
2. Recovery of neutropenia: > 500 neutrophils/μL
3. Removal of the catheter for any cause
4. Episode of CRBSI
5. Need to use the CVC for the administration of a
medication in continuous infusion that cannot be
stopped for any reason
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6. Discharge from the haematology ward for any reason,
despite not having recovered from the neutropenia
7. Death
Once the patient concludes the study for any of the previ-
ous events, a 30-day follow-up will take place to assess pos-
sible complications until that date. The intervention will be
stopped in patients in whom significant colonisation of a
CVC hub is detected, but they will continue to be followed-
up to check whether they develop CRBSI. Whenever the
catheter is removed on suspicion of infection, the hubs and
tip of the catheter will be sent for microbiological culture.
A patient will be considered to have discontinued the
study when the patient withdraws the informed consent,
dies, or is lost to follow-up. The trial will be considered
finished when all the recruited participants have com-
pleted the 30-day follow-up period. Figure 1 shows the
participant timeline of the study.
Interruption criteria
1. Withdrawal of consent
2. Violation of masking
3. Violation of the inclusion/exclusion criteria
4. Serious adverse reaction
In accordance with the current revision of the Declar-
ation of Helsinki and the applicable regulations, a pa-
tient has the right to withdraw from the study at any
time and for any reason, without this causing any harm
to the medical care by their physician. The withdrawal
of full consent from a study means that the patient does
not wish to continue participating in the study. Any pa-
tient withdrawing their consent will be removed from
the treatment and/or the study observations immediately
after the date the patient requests it.
Data collection
The following data will be collected: sex, age, type of under-
lying disease, other comorbidities, date of hospital admis-
sion, HSCT, type and date of HSCT, immunosuppressive
therapy, concomitant medication, duration of neutropenia,
type of CVC, days from CVC insertion to inclusion in the
study, use of prophylactic antibiotics or antifungal agents,
systemic antibiotic therapy, number of catheter locks per
episode, results of the cultures of the hubs and CVC inser-
tion site, any episodes of infection, episodes of CRBSI, the
need for CVC removal and reason, development of compli-
cations, adverse reactions, overall case-fatality rate, CRBSI
attributable case-fatality rate, and date of discharge.
Definitions
Significant colonisation of any catheter hub will be de-
fined as the presence of any microbial growth in the
qualitative culture of the swabs. CRBSI will be defined as
the detection of growth of bacteria or fungi in at least
one blood culture obtained from a peripheral vein,
associated with clinical signs and symptoms of infection
(e.g. fever, chills, and/or hypotension), and no apparent
source for BSI other than the CVC. In the case of com-
mon skin-colonising microorganisms, such as CNS, two
positive sets of blood cultures will be necessary to make
the diagnosis of CRBSI. CRBSI attributed to luminal
colonisation will be defined as the isolation of identical
organisms from the catheter hub and from cultures of
separate percutaneously drawn blood specimens; the
organism’s identity will be proven by molecular typing
for patients with BSI due to CNS. Overall, the 30-day
case-fatality rate will be defined as death by any cause
within the 30 days following the end of the intervention.
Study outcomes and endpoint assessment
Primary endpoint
For the assessment of the primary endpoint (bacterial
colonisation rate of the CVC hubs), swabs of the inner
surfaces of the catheter hubs will be obtained by the
nursing personnel before randomisation and three times
weekly (approximately every 48-72 h) thereafter for cul-
ture, until the end of the intervention. All swabs are
made of viscose, and only the swab of the catheter inser-
tion site has a transport media (Stuart media). One swab
is used for each lumen The cultures of the collected
swabs will be processed in the microbiology department.
The results of the cultures will be reviewed by the par-
ticipating investigators and will be written down in the
data collection form and in the specific database.
Secondary endpoints
The assessment of the secondary endpoints will be per-
formed as follows:
1. Incidence of CRBSI: swabs of the insertion site and
catheter hubs as well as blood cultures (at least one
from a peripheral vein) will be obtained when
CRBSI is suspected. In the case of catheter removal,
two 5-cm segments, a proximal subcutaneous
segment and the tip, will be sampled using the
sterile technique for culture. The incidence of
CRBSI and the CRBSI attributed to luminal
colonisation will be calculated for each group. The
differential time to positivity will not be used to
diagnose CRBSI. The development of CRBSI will be
assessed during intervention and up to 30 days after
the last intervention. The rate of CRBSI will be
presented as the number of episodes of CRBSI per
1000 admission days
2. CVC removal: whenever it is necessary to remove
the CVC because of occlusion, thrombosis,
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Fig. 1 Participant timeline of the study
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dislodgement or suspicion and/or documentation of
infection, the tip is going to be sent for culture to
the microbiology department, and the reasons for
removal will be annotated in the data collection
form and the database by the participating
investigators. The need for CVC removal will be
assessed during intervention and up to 30 days after
the last intervention
3. Adverse reactions: any adverse reaction potentially
associated with the administration of the lock
solution will be annotated in the data collection
form and the database by the participating
investigators. Adverse events will be identified and
classified according to the severity and the potential
relationship with the lock solution. They will be
assessed during the intervention
4. Overall (30-day) case-fatality rate: all patients
included in the study will be followed up for a total
of 30 days after the end of the intervention by the
participating investigators. Death by any cause will
be annotated in the data collection form and
the database
The research nurse in charge of the study will visit the
patients daily in order to collect all the data related to
the study. Also, the nurse will assess the potential
development of any adverse event, and will collect all the
information in the database. Adverse events will be
classified according to their severity and causality.
Only the serious adverse events, and those considered
to be related to the use of the product of the study
will be reported to the study promoter and to the
regulatory authorities.
Sample size
According to our previous experience [26], we estimated
that around 20% of patients in the control group will
present positive cultures of the catheter hubs. A reduc-
tion of this figure to 5% in the taurolidine-citrate-
heparin group would be clinically relevant. To detect a
15% difference between groups with a power of 80%, it
would be necessary to include 135 patients in the study.
Considering the possibility of a loss of 10% of cases, the
final sample should be 150 patients.
Statistical analysis
The analysis of the data will be carried out during the
last 6 months of the project when all fieldwork has been
completed. The database will then be analysed using the
stepwise logistic regression model of the R software
(R v. 3.2.5). The analyses will be made by intention-to-
treat (all patients randomised who have a primary endpoint
available). To handle missing data multiple imputation will
be done under the missing at random assumption.
For the analysis of the primary endpoint, the frequency
of colonisation of the CVC hubs in both treatment
groups will be compared. For the analysis of the second-
ary endpoints, the frequency of CRBSI will be compared
between the two groups, as well as the need for CVC
removal for any cause and overall case-fatality rate
(30 days). Exploratory subgroup analyses will be conducted
by underlying haematological condition (leukaemia,
autologous HSCT, and allogeneic HSCT) and by centre.
Due to the fact that a patient could have been included
twice, the potential impact of independence violation will
be assessed repeating the main analysis using patient
as a cluster.
The statistical analysis will be carried out using a
Student’s t test and a chi-square test. A multivariate ana-
lysis will be performed to verify the absence of confusion
by other variables. In addition, free time of colonisation of
the catheter and BSI will be analysed using Kaplan-Meier
curves, and they will be compared between both groups
by means of the log-rank test (Mantel-Cox test). A value
of p = 0.05 will be considered statistically significant.
Microbiology studies
Samples from the catheter hubs and insertion site will be
obtained using sterile swabs and plated in blood agar
plates. A qualitative culture of these samples will be per-
formed, and they will be considered positive when the
growth of a microorganism is detected. After catheter re-
moval, the terminal portion (5 cm) of the catheter tip will
be cultured using the roll-plate technique (Maki’s tech-
nique) [33]. A bacterial count > 15 CFU will be considered
significant. Blood cultures will be processed with the usual
system in the microbiology laboratories of the participat-
ing centres (BACTEC FX, Becton Dickinson, BD, Madrid,
Spain). The antibiotic susceptibility will be tested by disc
diffusion and microdilution methods following the
European Society of Clinical Microbiology and Infectious
Diseases (EUCAST) recommendations and breakpoints.
In the case of CRBSI due to coagulase-negative staphylo-
cocci (CNS), if the same species are isolated in any of the
catheter hubs or tip and in the blood cultures, the strains
will be preserved frozen for further analysis. CNS isolates
from blood and catheter samples will be sent to the micro-
biology laboratory of HUB. Species identification will be
confirmed using MALDI-TOF (MALDI Biotyper, Bruker
Daltonics, Germany). Finally, isolates will be studied by
pulsed-field gel electrophoresis after restriction with SmaI
in order to determine the intrapatient genetic relationship
following the criteria described by Tenover [34].
Monitoring
In compliance with the standards of Good Clinical Practice,
the promoter will carry out the monitoring tasks of the
study following the approved monitoring plan. Among
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others, the tasks of monitoring will include the assessment
of the correct application of the inclusion and exclusion cri-
teria, the assessment of the quality of the data collected, the
maintenance of the blind, the development and reporting
of any adverse events, and the maintenance of the confi-
dentiality of the patients. The need for a Data Monitoring
Committee (DMC) was waived by the Ethic Committee be-
cause of the low impact on the safety of the patients in the
study. Also, no interim analyses were planned.
Publication plan
Results will be reported at conferences and in peer-
reviewed publications. The first publication will be based
on data from the two participating centres and will be
analysed as stipulated in the protocol with the statisticians’
supervision. Any formal presentation or publication of
data collected from this study will be considered as a joint
publication by the participating investigators and will fol-
low the recommendations of the International Committee
of Medical Journal Editors.
Discussion
This large prospective, multicentre, randomised, double-
blinded, placebo-controlled trial aims to test the hypoth-
esis that lock solution with taurolidine-citrate-heparin is
more effective than placebo for preventing CVC catheter
infection in high-risk neutropenic haematological pa-
tients and, consequently, CRBSI.
Various strategies to reduce the incidence of CRBSI
have been evaluated, including the use of antibiotic-
impregnated catheters, strict hygienic measures, eradica-
tion of S. aureus nasal carriage, and application of
prophylactic antibiotic ointment on the insertion site
[35]. However, catheter infection still occurs, especially
with long-term CVC use. Given the integral role of
long-term CVC use in the health care system, adminis-
tering lock solutions to patients with these types of cath-
eters remains an important option for the prevention
and adjunctive treatment of CRBSI. The lock technique
is a preventive strategy that inhibits bacterial colonisa-
tion in the catheter hubs, which is the initial step of
endoluminal catheter colonisation and the development
of infection [13, 14].
A wide variety of antibiotic lock solutions have been eval-
uated for clinical use, with the largest body of data available
for vancomycin and gentamicin [17]. In this regard, in a
meta-analysis, vancomycin-containing lock or flush solu-
tions had shown to reduce CRBSIs and prolonged catheter
survival in patients receiving haemodialysis [36].
Patients with cancer who have a CVC implanted are at
special risk of developing CRBSI. Infection rates of 2.66
per 1000 line-days have been found in adult haematology/
oncology and bone marrow transplant units [37]. Re-
cently, lock solution technique as a preventive strategy for
CRBSI in patients with cancer has been systematically
reviewed [19]. The great majority of studies were per-
formed in paediatric patients (10 studies), and only three
were carried out in the adult population. Vancomycin was
the most frequently studied solution because the great
majority of infections are caused by Gram-positive bac-
teria. The results of vancomycin studies were variable;
some studies showed a reduction of CRBSI in paediatric
patients with cancer [23, 25], while others failed to do so
[24]. Moreover, Carratalà et al. [26] demonstrated a sig-
nificant reduction of CRBSI in neutropenic haematological
patients using vancomycin as lock solution in the single
study carried out in adults. Nevertheless, the widespread
use of prophylactic antibiotics as catheter lock solutions
may contribute to the development of antibiotic-selective
pressure and resistance. In addition, the emergence of
Gram-negative bacteria as an important cause of CRBSI
raises the doubt about the current utility of vancomycin.
Furthermore, three studies investigating ethanol as a lock
solution in paediatric and adult patients with cancer
showed discordant results [20–22]. Moreover, relatively
frequent adverse effects have been reported with the use
of ethanol-based solutions, which limits its use for this
purpose [21, 22].
Taurolidine is a non-toxic agent with antimicrobial ac-
tivity against Gram-positive bacteria, Gram-negative
bacteria, and fungi. It reduces biofilm formation and
does not develop antibiotic resistance because it acts
as an antiseptic rather than an antibiotic [30]. Inter-
estingly, due to its broad-spectrum antibacterial activity,
taurolidine-citrate used as a lock solution not only re-
duced the risk of CRBSI but also the risk of Gram-
negative infections according to the results of a recent
meta-analysis conducted in the general population with-
out cancer [18]. In the aforementioned systematic review
in patients with cancer by Norris et al. [19], taurolidine
showed beneficial results compared with placebo in two of
the three studies involving paediatric patients with cancer
[28, 29]. On the contrary, a third study of paediatric pa-
tients with totally implantable venous access ports showed
no beneficial effect [27]. Likewise, in a recent prospective,
randomised, phase IV trial, taurolidine-citrate did not
show a significant reduction in the risk of infection when
used in adult patients with non-haematological cancer
[31]. These studies have important limitations due to the
lack of data on adult and/or high-risk neutropenic pa-
tients, the type of catheters studied (tunnelled or ports),
and the lack of information regarding the intervention
(e.g. dwelling of the solution, time, and periodicity of
the lock technique).
The use of taurolidine-citrate as a lock solution has
been associated with mild and self-limited adverse
events when used as flushing, with an unpleasant taste
in the mouth as the most common side effect.
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In this study, we aim to assess the efficacy of
taurolidine-citrate as a catheter lock solution in prevent-
ing CVC bacterial colonisation and, consequently,
CRBSI in neutropenic haematological patients. If our hy-
pothesis is proven, the study could provide important
solid evidence on the potential usefulness of this pre-
ventive procedure in a population at high risk of CRBSI,
in whom this complication may significantly impair
patient outcome.
Trial status
Recruitment of patients started on 1 January 2013, and it
will be completed by 30 June 2018. Protocol version
number 5.0. Date: 27 July 2016.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOCX 36 kb)
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